← brief for 2026-09-11 · Slowing decline

Complement in Kidney Disease: Core Curriculum 2026

Key takeaways

This is a teaching review about complement, a part of the immune system that fights infection but can also attack the kidney when it misfires. It explains that the US Food and Drug Administration has now approved complement-blocking drugs for five kidney diseases, including atypical hemolytic uremic syndrome and C3 glomerulopathy. It is a summary of what is already known, so there is no new data here. Useful as background if your diagnosis involves immune-driven kidney damage.

Source

Paper · AJKD · 2026-09-11
https://www.ajkd.org/article/S0272-6386(26)01049-8/fulltext?rss=yes